22157.jpg
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials
June 20, 2024 06:59 ET | Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
RM Primary Logo - Humble.png
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
22157.jpg
Analysis of the KRAS Mutant Cancer Pipeline, 2024: Emerging Therapies, Key Players, Unmet Needs and More
May 30, 2024 04:30 ET | Research and Markets
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "KRAS Mutant Cancer - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive...
cmi_logo.png
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
May 15, 2024 09:00 ET | Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
RM Primary Logo - Humble.png
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Cardiff.jpg
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 02, 2024 16:05 ET | Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET | Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
May 02, 2024 02:30 ET | Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
May 01, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...